A detailed history of Fjarde Ap Fonden transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Fjarde Ap Fonden holds 27,815 shares of ALNY stock, worth $6.77 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
27,815
Previous 27,415 1.46%
Holding current value
$6.77 Million
Previous $4.1 Million 86.72%
% of portfolio
0.08%
Previous 0.05%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$233.81 - $287.01 $93,524 - $114,804
400 Added 1.46%
27,815 $7.65 Million
Q1 2024

Apr 25, 2024

SELL
$146.51 - $198.2 $73,255 - $99,100
-500 Reduced 1.79%
27,415 $4.1 Million
Q4 2023

Feb 14, 2024

SELL
$151.41 - $196.57 $75,705 - $98,285
-500 Reduced 1.76%
27,915 $5.34 Million
Q3 2023

Oct 23, 2023

SELL
$170.77 - $211.65 $17,077 - $21,165
-100 Reduced 0.35%
28,415 $5.03 Million
Q2 2023

Aug 02, 2023

SELL
$185.01 - $212.05 $259,014 - $296,870
-1,400 Reduced 4.68%
28,515 $5.42 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $182,660 - $235,530
1,000 Added 3.46%
29,915 $5.99 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $333,954 - $434,358
-1,800 Reduced 5.86%
28,915 $6.87 Million
Q2 2022

Aug 11, 2022

SELL
$120.42 - $169.29 $710,478 - $998,811
-5,900 Reduced 16.11%
30,715 $4.48 Million
Q1 2022

May 13, 2022

SELL
$127.18 - $173.91 $419,694 - $573,903
-3,300 Reduced 8.27%
36,615 $5.98 Million
Q4 2021

Feb 15, 2022

SELL
$159.56 - $209.29 $154,613 - $202,802
-969 Reduced 2.37%
39,915 $6.77 Million
Q3 2021

Nov 15, 2021

SELL
$169.75 - $207.73 $135,800 - $166,184
-800 Reduced 1.92%
40,884 $7.72 Million
Q2 2021

Aug 12, 2021

BUY
$128.63 - $176.89 $128,630 - $176,890
1,000 Added 2.46%
41,684 $7.07 Million
Q1 2021

May 17, 2021

BUY
$126.83 - $175.69 $202,928 - $281,104
1,600 Added 4.09%
40,684 $5.74 Million
Q4 2020

Feb 12, 2021

SELL
$122.97 - $147.0 $282,831 - $338,100
-2,300 Reduced 5.56%
39,084 $5.08 Million
Q3 2020

Nov 13, 2020

BUY
$121.19 - $165.49 $302,975 - $413,725
2,500 Added 6.43%
41,384 $6.03 Million
Q2 2020

Aug 13, 2020

SELL
$104.21 - $156.44 $135,473 - $203,372
-1,300 Reduced 3.24%
38,884 $5.76 Million
Q1 2020

May 11, 2020

BUY
$93.12 - $133.99 $307,296 - $442,167
3,300 Added 8.95%
40,184 $4.37 Million
Q4 2019

Feb 10, 2020

BUY
$74.51 - $124.23 $439,609 - $732,957
5,900 Added 19.04%
36,884 $4.25 Million
Q3 2019

Oct 31, 2019

BUY
$70.9 - $87.82 $517,570 - $641,086
7,300 Added 30.82%
30,984 $2.49 Million
Q2 2019

Jul 17, 2019

SELL
$65.86 - $92.79 $335,886 - $473,229
-5,100 Reduced 17.72%
23,684 $1.72 Million
Q1 2019

Apr 29, 2019

BUY
$72.76 - $93.45 $257,352 - $330,532
3,537 Added 14.01%
28,784 $2.69 Million
Q4 2018

Jan 31, 2019

SELL
$62.67 - $88.33 $213,078 - $300,322
-3,400 Reduced 11.87%
25,247 $1.84 Million
Q3 2018

Nov 09, 2018

SELL
$87.52 - $122.67 $89,708 - $125,736
-1,025 Reduced 3.45%
28,647 $2.51 Million
Q2 2018

Jul 12, 2018

BUY
$88.31 - $107.8 $131,316 - $160,298
1,487 Added 5.28%
29,672 $2.92 Million
Q1 2018

May 07, 2018

SELL
$115.92 - $148.54 $127,512 - $163,394
-1,100 Reduced 3.76%
28,185 $3.36 Million
Q4 2017

Feb 12, 2018

BUY
$114.49 - $139.98 $3.35 Million - $4.1 Million
29,285
29,285 $3.72 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Fjarde Ap Fonden Portfolio

Follow Fjarde Ap Fonden and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.